Probing the Effect of Point Mutations at Protein-Protein Interfaces with Free Energy Calculations  by Almlöf, Martin et al.
Probing the Effect of Point Mutations at Protein-Protein Interfaces
with Free Energy Calculations
Martin Almlo¨f,* Johan A˚qvist,* Arne O. Smala˚s,y and Bjørn O. Brandsdaly
*Department of Cell and Molecular Biology, Uppsala University, Biomedical Centre, Uppsala, Sweden; and yThe Norwegian Structural
Biology Centre, Faculty of Science, University of Tromsø, Tromsø, Norway
ABSTRACT We have studied the effect of point mutations of the primary binding residue (P1) at the protein-protein interface in
complexes of chymotrypsin and elastase with the third domain of the turkey ovomucoid inhibitor and in trypsin with the bovine
pancreatic trypsin inhibitor, using molecular dynamics simulations combined with the linear interaction energy (LIE) approach. A
total of 56 mutants have been constructed and docked into their host proteins. The free energy of binding could be reliably
calculated for 52 of these mutants that could unambiguously be ﬁtted into the binding sites. We ﬁnd that the predicted binding
free energies are in very good agreement with experimental data with mean unsigned errors between 0.50 and 1.03 kcal/mol. It
is also evident that the standard LIE model used to study small drug-like ligand binding to proteins is not suitable for protein-
protein interactions. Three different LIE models were therefore tested for each of the series of protein-protein complexes
included, and the best models for each system turn out to be very similar. The difference in parameterization between small
drug-like compounds and protein point mutations is attributed to the preorganization of the binding surface. Our results clearly
demonstrate the potential of free energy calculations for probing the effect of point mutations at protein-protein interfaces and for
exploring the principles of speciﬁcity of hot spots at the interface.
INTRODUCTION
Protein-protein interactions play essential roles in many
biological processes such as enzyme regulation, signal trans-
duction, and immune response. Understanding how protein-
protein complexes form and what determines their speciﬁcity
is not only fundamental to understanding these biological
processes but also helpful in inhibitor design. To date, much
work has been done to develop computational procedures to
predict and evaluate these interactions, and the efforts de-
voted to protein-protein docking are extensive (for reviews,
see, e.g., Halperin et al. (1) or Smith and Sternberg (2)).
Typically, these methods utilize surface complementarity,
buried surface area, atomic solvation parameters, continuum
models, or a combination of the above to ﬁnd the best dock-
ing pose. Once the interaction mode is predicted or known, it
is of interest to examine what determines the speciﬁcity of
the interaction. From alanine-scanning experiments, it has
been determined that typically the interface consists of a hot
spot of residues that accounts for a major part of the binding
free energy (3). Site-directed mutagenesis of these hot spot
residues can then give some insight into the factors that
determine speciﬁcity. Several computational techniques exist
that can be used to predict relative binding free energies of
protein-protein association, including free energy perturba-
tion (FEP) (see, e.g., Brandsdal et al. (4) or Kollman (5)),
linear interaction energy (LIE) (6,7) and MM-PBSA (molec-
ular mechanics-Poisson-Boltzmann surface area) (8) meth-
ods as well as those based solely on buried surface area in
combination with atomic solvation parameters (9). Although
FEP and other similar computer simulation techniques, such
as thermodynamic integration, offer a rigorous statistical me-
chanical way to calculate free energies of binding, they suffer
from long computational times and technical difﬁculties as-
sociated with creation and annihilation of atoms. If only the
relative binding free energies of a set of mutants is required,
and the structural differences between the mutants are
small, FEP may nevertheless be a viable method. MM-PBSA
approximates free energies using a Poisson-Boltzmann con-
tinuum representation of the solvent together with a surface-
area-dependent term and molecular mechanics energies using
snapshots from MD (molecular dynamics) simulations gen-
erated with explicit solvent. This method has been applied to
predict, e.g., the relative stabilities of A-DNA and B-DNA
(8) and effects of alanine mutations on protein-protein inter-
actions (10). Although the MM-PBSA approach has several
appealing features compared to the more rigorous FEP/TI
methods, particularly when dealing with binding of diverse
sets of ligands that are structurally and chemically different,
the free energies of binding are usually computed based on
simulations of only the bound state. Hence, the normal im-
plementation of this method assumes that the structure of
the receptor and the ligand does not change upon binding.
Another problem associated with the MM-PBSA approach is
how to determine the contribution from entropy changes in-
volved in binding. If absolute free energies are required the
entropic contribution must be determined to yield meaning-
ful results. This is extremely difﬁcult since conformational
ﬂuctuations generally change upon binding, and for relative
binding free energies the entropic term is often assumed to
Submitted August 29, 2005, and accepted for publication October 6, 2005.
Address reprint requests to Bjørn O. Brandsdal, The Norwegian Structural
Biology Centre, Faculty of Science, University of Tromsø, N-9037 Tromsø,
Norway. Tel.: 477-764-4057; Fax: 477-764-4765; E-mail: Bjorn-Olav.
Brandsdal@chem.uit.no.
 2006 by the Biophysical Society
0006-3495/06/01/433/10 $2.00 doi: 10.1529/biophysj.105.073239
Biophysical Journal Volume 90 January 2006 433–442 433
cancel (11), which is still a severe approximation. Coura-
geous attempts have been made by Gohlke and Case (12) to
evaluate all formally relevant MM-PBSA terms for the Ras-
Raf complex, which clearly illustrates the magnitude of the
convergence problems.
The LIE method was originally developed to predict
binding of drug-size ligands to proteins using MD or MC
(Monte Carlo) simulations. It relies on the electrostatic linear
response approximation to predict the electrostatic contribu-
tion to the binding free energy and an empirical scaling of
the intermolecular van derWaals (Lennard-Jones) energies to
predict the nonpolar contribution to the binding free energy
according to
DGbind ¼ aDÆVvdWls æ1bDÆVellsæ1 g; (1)
where the Ææ’s denote MD or MC averages of the ligand-
surrounding van der Waals or electrostatic energies, and the
D’s denote the difference between these averages in the
bound and free states. The electrostatic energies are scaled by
a ligand-dependent parameter, b, which can take on a few
different values in the range 0.33–0.50 (13). The van der
Waals energies are scaled by an empirically determined co-
efﬁcient, a. In studies performed previously in our labo-
ratory, an a of 0.18 has reproduced the binding free energies
of various ligand-protein systems well, and it has been
shown that a is neither system-dependent nor force-ﬁeld-
dependent for the ligand-protein systems and force ﬁelds
examined to date (14). g is a constant term reﬂecting bind-
ing-site hydrophobicity that may be required to reproduce
absolute binding free energies (14), but is not necessary for
relative binding free energies.
The initial idea behind the LIE method was to consider the
binding free energy as the change in solvation energy of the
ligand when it is transferred from solution to the binding site
of the receptor:
DGbindðlÞ ¼ DGpsolðlÞ  DGwsolðlÞ; (2)
where l represents a ligand and p and w denote protein and
water, respectively. This process can formally be considered
to consist of two separate steps: 1), creation of a van der
Waals cavity in the given environment; and 2), turning on the
electrostatic interactions between the ligand and its sur-
roundings (6). The electrostatic part of the solvation/binding
free energies is treated with the linear response approxima-
tion, and the linear response result for solvation in a given






where the Ææ values are MD (or MC) averages sampled with
the electrostatic interactions between the ligand and its
surroundings (solvated protein or water) turned on and off,
respectively. The latter average formally requires an extra
simulation of an unphysical ‘‘nonpolar ligand’’ state to be
carried out, and a central approximation in the LIE approach
is that the term ÆVellsæoff can be neglected, which has been
found to hold well in water (13). The ÆVellsæoff term is often
thought of as an electrostatic preorganization term. It is not
surprising that this term is zero in water, since the orienta-
tions of the water molecules relative to a completely non-
polar solute will be largely random, i.e., the water molecules
are not preorganized with respect to the solute electrostatic
potential. However, in the binding site of an enzyme, for
instance, the backbone and side chains of the amino acids
that make up the binding site are most likely not randomly
oriented. The extent of this nonrandomness and how much
the binding site relaxes upon binding/unbinding of a ligand
will greatly affect the size of ÆVellsæoff .
We have previously applied the LIE approach to study the
effect of point mutations of the primary binding residue (P1)
of bovine pancreatic trypsin inhibitor (BPTI) bound to
trypsin (16). The complexes between serine proteinases and
their canonical protein inhibitors are excellent systems to test
protein-protein recognition models on as there is plenty of
experimental binding data on different P1 mutations, and the
P1 residue has been found to be responsible for up to 70% of
the total association energy (17). By treating the P1 residue
as the ligand in the LIE method the effect of mutating it to
other amino acids can be estimated. In this study, we report
the successful prediction of binding free energies for several
mutants of BPTI to trypsin and several mutants of the third
domain of the turkey ovomucoid inhibitor (OMTKY3) to
elastase and chymotrypsin using the LIE method together
with MD simulations. We have further tried to push the
computational efﬁciency by using relatively small simulation
systems and short simulations (;250 ps), while requiring
convergence errors in DGbind to be ,61:0 kcal/mol. Our
previous calculations dealing with P1 mutations of BPTI
bound to trypsin used a ¼ 0:18 (16). In this study, we have
expanded the data set used in our previous study (13
mutations on trypsin-BPTI), which now includes 56 mutants
of three different proteinase-protein inhibitor complexes.
Our previous calculations also estimated the effect of point
mutations relative to P1 Gly, for which the absolute binding
energy turns out to have been an outlier, affecting the ob-
tained value for a. Instead of relying on a single reference
state we now estimate the absolute binding free energy for
each variant. The predicted free energies of binding are in
excellent agreement with experiments with average unsigned
errors of 0.74, 0.50, and 1.03 kcal/mol for chymotrypsin,
elastase, and trypsin, respectively.
METHODS
Complexes between bovine b-trypsin and BPTI, and human leukocyte
elastase (HLE) and a-chymotrypsin both in complex with OMTKY3, were
subjected to MD simulations with the software package Q (18) and the
OPLS-AA force ﬁeld (19). Substitution of the primary binding residue with
the remaining natural amino acids gives a total of 20 different complexes for
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each system. In the case of trypsin-BPTI, 10 different x-ray structures dif-
fering only in the nature of the amino acid at the P1 position were available
(20), whereas the remaining complexes were constructed by manually
changing the P1 residue using the crystallographic software O (21). The
series for HLE and chymotrypsin were generated starting from the crystal
structures with Protein Data Bank entries 1PPF (22) and 1CHO (23),
respectively, and manual adjustments of the P1 side chain, again using O.
Complexes in which the P1 residue is proline were omitted in all three series
as this residue imposes major changes in the orientation of the backbone.
Thus, a total of 19 different complexes were investigated with MD sim-
ulations for each enzyme. In the case of OMTKY3 P1 Tyr binding to HLE,
the MD simulations were not completed, as it was not possible to obtain
a minimized structure without steric clashes at the S1 site of the complex,
even though several orientations of the P1 side chain were tested. Hence, 18
MD simulations were carried out for HLE.
The Ca-atom of the P1 residue was deﬁned as the center of a 16-A˚ sphere
for which unrestrained MD simulations were carried out. Atoms in the
outermost 3 A˚ were weakly restrained (harmonic restraint of 5 kcal/mol A˚2)
to their crystallographic positions, whereas atoms outside the 16-A˚ sphere
were strongly restrained (harmonic restraint of 200 kcal/mol A˚2). Non-
bonded interactions across the boundary were excluded. The nonbonded
potential was truncated at 10 A˚ while long-range electrostatics were treated
using a multipole expansion (24). The interactions involving the P1 residue
were not truncated and thus were allowed to interact with the entire
simulation sphere. Crystallographic water molecules closer than 12 A˚ from
the reaction center were retained, and additional solvent molecules were
added to ﬁll the 16-A˚ sphere. Water molecules were described using the
TIP3P model (25). All systems were heated from 1 to 300 K using a stepwise
scheme followed by an equilibration period to stabilize ligand-surrounding
energies before the data collection phase. During the heating phase, heavy
atoms (protein and crystallographic water) were restrained to the initial
positions using a harmonic potential with a force constant of 5 kcal/(mol A˚2).
The timestep used in the production phase of the simulations was 1.5 fs, and
the temperature was set to 300 K using a weak coupling to an external bath.
SHAKE (26) was used to constrain bonds and angles on solvent molecules.
The total simulation time for the production period was 225 ps for most
simulations. Energies were sampled every ﬁfth step in the production part of
the simulations. These energies were then used in Eq. 1 to obtain the free
energy of binding. The convergence of the simulations is judged by dividing
the trajectory in two halves and then calculating the free energy for each of
these two halves. If this energy differs by.2.0 kcal/mol, the simulation was
further extended (up to 750 ps in a few cases). This also provides an estimate
of the convergence error in the computed binding energies, which is on
average ,1.0 kcal/mol.
To avoid possible Born terms entering into the calculated free energies
the net charge, excluding the P1 residue, within the simulation sphere in the
complex and the free inhibitors is set to zero. This is done by using the neutral
form for ionic residues that are close to the boundary and those outside the
simulation sphere as described previously (16,27). Alternatively, counterions
can be added to neutralize these ionizable residues. This may, however, slow
down the convergence of the free energy calculations as such ions are often
highly mobile in the simulations. The contribution from the ionic residues
described as neutral is then added to the computed binding energy by using
a Coulombic potential with a high dielectric constant (28). This contribution
can also be estimated by using continuum electrostatic calculations, but this
has been found to yield results virtually identical to those produced using
a Coulombic potential with a high dielectric constant (27).
The LIE optimizations are performed by calculating the values of the
coefﬁcients that are considered as free, which minimize the root mean square
deviation between the calculated and the experimental binding energies. The
coefﬁcient of multiple determination, R2, is a measure of the overall ﬁt of the
model and is calculated as: R2 ¼ 1 SSE=SST, where SSE is the square sum
of errors SSE ¼ +
i
ðDGcalci  DGobsi Þ2 and SST is the total sum of squares
SST ¼ +
i
ðDGobsi  DGobsaveÞ2. To assess overﬁtting, the cross-validated
statistical ﬁgure of merit Q2 was also calculated. Q2 ¼ 1 PRESS=SST,




j¼1ðDGobsi;j  DGcalci;j Þ2, where pmut is the
number of permutations of leaving n ligands out of the parameterization.
DGobsi;j and DG
calc
i;j are the observed and calculated binding free energies of
the j’th ligand in the i’th permutation. In this study the number of leave-outs
was set to 3. The cross-validated standard deviation, sPRESS, explicitly takes
into account the number of free parameters and is calculated according to:
sPRESS ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
PRESS=ðn p 1Þp , where n is the data set size, and p is the
number of optimized parameters in the model.
RESULTS AND DISCUSSION
X-ray analysis of complexes between serine proteinases and
their canonical protein inhibitors (20,29) shows that even
though the interactions in the principal interaction zone
change in response to the nature of the amino acid at the P1
site, the secondary interactions are virtually identical and in-
dependent of the P1 residue. This means that for a given
series of complexes differing only in the P1 position of the
protein inhibitor, the free energy contribution from the sec-
ondary subsites will be similar. Within the LIE framework,
the P1 residue is treated as a ‘‘ligand’’, and its interactions
with the surroundings are measured in the bound and un-
bound states, and the rest of the protein inhibitor is con-
sidered as part of the surroundings. The main advantage of
using this strategy is that the interaction energies of the P1
residue converge quite rapidly in the MD simulations, which
is of course not the case if the entire protein inhibitor is
treated as a ligand. Calculation of absolute protein-protein
binding energies with the LIE approach would require that
one obtains convergent values of the entire interaction
energies, and these quantities can be in the order of several
thousand kcal/mol. This would require extremely long simu-
lations to get stable averages and result in an inefﬁcient ap-
proach with corresponding high uncertainties in the energetics.
However, because the secondary interactions are assumed to
be identical for all the 20 possible complexes between a given
proteinase and a protein inhibitor where only the P1 residue
is different, only a constant term (g) is needed to account for
the contribution from the secondary binding sites to the free
energy.
Many recent studies of ligand binding (30–36) have de-
termined that a value of 0.18 for a adequately reproduces the
free energies of binding for a variety of ligand-protein sys-
tems. In those systems the ligands were primarily of drug-
like character, particularly their size. That is not the case with
this study, where the ligand is a small protein, and hence the
standard parameterization with a ¼ 0.18 turns out not to
hold. To examine other possible LIE models, two new
parameterizations were investigated: model A uses the
b-coefﬁcients from Hansson et al. (31) assuming a value of
either 0.37, 0.43, or 0.50, depending on the chemical nature
of the P1 residue, while a and g are optimized; in model B,
all three parameters are freely optimized. Model C is the
standard LIE model, where a ¼ 0.18, b is ligand-dependent
(as in model A), and g reproduces the secondary interactions.
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The calculated average ligand-surrounding interaction
energies from the MD simulations of the a-chymotrypsin,
human leukocyte elastase, and bovine trypsin systems are
shown in Tables 1–3. Based on these energies, the three
different LIE models were tested (Table 4) and their statistical
ﬁgures of merit calculated. As is seen by the statistical ﬁgures
ofmerit, model C fails for all three systems, whereasmodels A
and B perform very well. Overall, the model that fares best is
model A, with only a and g as free parameters. For
chymotrypsin, elastase, and trypsin the values of a necessary
to reproduce experimental results are 0.63, 0.56, and 0.54,
respectively. Fig. 1 shows the observed versus calculated
experimental binding free energies of the three systems using
model A. Out of the total 56 complexes, four elastase
complexes with large P1 variants that do not ﬁt into the
crystallographic S1 binding pocket were excluded in the
statistical analysis and these cases are further discussed below.
The LIE model that provides the best correlation between
calculated and experimental binding free energies is virtually
identical for the three enzymes studied here. Although the
polar contribution is treated in the same fashion as in the
previous LIE models (31), the nonpolar contribution needs to
be treated with a different weight coefﬁcient (a) than pre-
viously (;0.58 compared to 0.18). In addition, the g-con-
stant that was originally set to zero is now used to obtain the
interaction free energy that arises from secondary subsites
through a calibration to reproduce the absolute binding free
energy. This constant will of course be system-dependent
and it can only be estimated when some experimental data is
available. Relative binding free energies can, however, be
calculated by leaving out the g-constant, as this will always
cancel out in DDGbind.
Effect of point mutations
The LIE calculations presented above show that we are able
to predict the outcome of point mutations at the protein-
protein interface between serine proteinases and their canon-
ical protein inhibitors. These calculations include series of
19, 18, and 19 different amino acids at the P1 position in
chymotrypsin-OMTKY3, elastase-OMTKY3, and trypsin-
BPTI complexes, respectively, yielding a total of 56 point
mutations. These calculations show a remarkable agreement
with the experimental binding data, and the amino acid
TABLE 1 Ligand-surrounding interaction energies from the MD
simulations of P1 variants of OMTKY3 free in solution and when
bound to chymotrypsin
Chymotrypsin-OMTKY3 OMTKY3




Gly 69.8 4.8 70.1 3.2 8.8 9.1
Ala 67.5 8.0 69.3 4.9 9.1 10.4
Ser 80.0 11.0 84.3 3.6 11.0 10.2
Cys 78.2 13.0 77.4 5.7 12.9 12.6
Val 70.7 15.5 69.6 8.9 12.3 10.9
Thr 81.4 11.2 83.0 5.6 10.9 10.7
Leu 71.0 21.7 71.3 10.7 14.8 15.1
Ile 65.0 22.0 70.4 10.6 12.8 10.7
Met 75.6 20.9 78.0 10.2 13.7 14.8
Asn 82.9 17.4 91.8 6.5 11.0 11.8
Asp0z 85.7 16.1 85.6 6.3 8.4 8.0
Lys0z 80.1 21.7 83.3 9.8 10.9 10.7
Gln 84.1 21.9 92.7 8.2 12.9 12.2
Glu0z 84.5 19.3 86.3 7.9 9.4 8.6
His 84.1 23.1 94.5 8.9 12.4 12.2
Phe 73.7 26.9 74.9 13.6 15.8 16.6
Arg0z 107.4 18.1 104.7 7.8 9.9 11.2
Tyr 84.0 27.8 86.1 11.9 17.2 17.3
Trp 78.7 31.6 83.6 15.8 15.8 16.8
Values are given in kcal/mol.
*Energies calculated according to DGLIEbind ¼ aDÆVvdWls æ1bDÆVellsæ1 g, and
the error in these values is ,1.0 kcal/mol. The coefﬁcients used are from
Model A in Table 4.
yExperimental binding data from Lu et al. (38).
z0 indicates a neutral side chain. DGLIEbind has been corrected with the free
energy required to protonate/deprotonate the ionic side chain according to
DDGpKabind ¼ 1:35jpH  pKaj; where pH is 8.3 (corresponding to the pH used
in the association measurements) and pKa is 12.5, 10.7, 4.5, and 4.0
for Arg(5.7 kcal/mol), Lys(3.2 kcal/mol), Glu(5.1 kcal/mol), and Asp(5.8
kcal/mol), respectively.
TABLE 2 Ligand-surrounding interaction energies from the MD
simulations of P1 variants of OMTKY3 free in solution and when
bound to elastase
Elastase-OMTKY3 OMTKY3




Gly 69.7 5.7 70.1 3.2 10.3 9.8
Ala 70.1 9.5 69.3 4.9 12.0 12.1
Ser 82.3 9.3 84.3 3.6 11.5 10.1
Cys 78.6 11.3 77.4 5.7 12.7 13.2
Val 67.4 16.9 69.6 8.9 12.6 13.6
Thr 77.3 14.9 83.0 5.6 12.1 12.2
Leu 71.1 16.9 71.3 10.7 12.4 13.1
Ile 68.3 20.0 70.4 10.6 13.4 13.8
Met 72.2 19.0 78.0 10.2 11.5 11.9
Asn 75.7 18.0 91.8 6.5 8.6 8.0
Asp0z 77.2 15.3 85.6 6.3 5.2 5.6
Lys0z 74.9 19.3 83.3 9.8 7.6 7.5
Gln 82.6 18.5 92.7 8.2 10.5 9.9
Glu0z 78.3 18.3 86.3 7.9 6.8 6.2
His 72.0 22.0 94.5 8.9 6.7 6.8
Phe 69.5 23.4 74.9 13.6 12.3 8.0
Arg0z 85.4 20.5 104.7 7.8 2.4 6.1
Tyr ND ND ND ND ND 6.7
Trp 71.2 27.2 83.6 15.8 10.2 5.7
Values are given in kcal/mol.
*Energies are calculated according to DGLIEbind ¼ aDÆVvdWls æ1bDÆVellsæ1g,
and the error in these values is ,1.0 kcal/mol. The coefﬁcients used are
from Model A in Table 4.
yExperimental binding data from Lu et al. (38).
z0 indicates neutral side chain. DGLIEbind has been corrected with the free
energy required to protonate/deprotonate the ionic side chain according to
DDGpKabind ¼ 1:35jpH  pKaj; where pH is 8.3 (corresponding to the pH used
in the association measurements) and pKa is 12.5, 10.7, 4.5, and 4.0 for
Arg(5.7 kcal/mol), Lys(3.2 kcal/mol), Glu(5.1 kcal/mol), and Asp(5.8 kcal/
mol), respectively.
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preference at the P1 position is indeed very different among
the three serine proteinases. Not only is the protein-protein
interface complementary in terms of shape (Fig. 2), but also
in terms of polar interactions. This is especially true for
binding of BPTI to trypsin with the cognate P1 Lys and Arg
variants. The active site of trypsin has been found to possess
a negative potential (37), which is matched by the positively
charged surface of BPTI. Our calculations also show that
mutations of P1 Lys and Arg to Gly has a tremendous effect
on the association energy, with a DDGLIEbind (Lys/Arg/ Gly)
of ;12 kcal/mol. Chymotrypsin, on the other hand, is found
to prefer large aromatic side chains (Tyr. Phe. Trp) at the
S1 site, whereas acidic residues are the most unfavorable.
This is also in perfect agreement with the experimental
mutagenesis study of Lu et al. (38). HLE prefers Ile at the S1
site according to both experimental and calculated binding
data, and again we ﬁnd that acidic side chains are unfavor-
able. Fig. 3 shows a structural comparison of the most- and
least-favored P1 variants accommodated at the S1 sites of
trypsin, chymotrypsin, and elastase. From this ﬁgure it is
apparent that even though the P1 side chain alters the
association energies greatly, the secondary interactions,
which are primarily main chain-main chain interactions,
are indeed virtually identical in the most- and least-favored
P1 variants for all three enzymes.
The calculations involving large side chains at the inter-
face of OMTKY3 and HLE are, however, problematic, since
the S1 site of elastase is much narrower compared to both
chymotrypsin and trypsin. This is primarily due to sub-
stitution of Gly-216 in chymotrypsin and trypsin for Val-216
in elastase. Docking of large aromatic P1 side chains, such as
Phe, Tyr, and Trp, into the S1 site of elastase is therefore not
possible without major steric clashes. This situation already
suggests that the assumption of constant secondary inter-
actions will not hold for these types of substitutions. Exper-
imentally it is also found that accommodation of the large
aromatic side chains to the S1 site of elastase is not favorable
and has a deleterious effect on the association energy relative
to the P1 Gly (38). When these P1 mutants are forced into the
binding site, subsequent LIE calculations indeed give a sig-
niﬁcantly too negative binding energy with the optimal model
(A) for elastase. This strongly suggests that the secondary
interactions at the interface are indeed weakened by the
required relaxation of the S1 site when Phe, Tyr, and Trp P1
variants bind. This could perhaps also be viewed as a loss
of preorganization of the binding site and will be further
TABLE 3 Ligand-surrounding interaction energies from the MD
simulations of P1 variants of BPTI free in solution and when
bound to trypsin
Trypsin-BPTI BPTI




Gly 71.6 5.5 70.0 3.5 5.3 5.6
Ala 71.4 10.6 69.0 5.7 7.2 7.3
Ser 90.5 10.3 82.8 4.4 9.6 10.2
Cys 81.5 12.4 78.3 6.1 8.3 ND
Val 71.6 17.8 69.6 8.9 9.2 6.2
Thr 87.1 13.2 81.3 6.8 9.1 7.4
Leu 69.5 20.5 69.8 11.0 8.5 9.1
Ile 69.4 18.0 68.8 11.5 7.3 6.8
Met 78.6 21.1 77.0 10.9 9.7 10.3
Asn 88.5 17.8 89.4 7.1 8.9 9.9
Asp0z 87.0 17.0 80.5 9.5 4.2 6.5
Lys§ 146.7 17.9 132.7 4.1 17.8 17.9
Gln 93.5 20.4 92.2 9.0 10.2 8.6
Glu0z 96.0 19.4 86.6 8.3 7.9 8.5
His 84.9 22.6 93.1 9.9 6.9 9.2
Phe 70.8 28.3 73.1 14.5 10.0 10.9
Arg§ 145.3 12.4 123.4 3.1 19.3 18.4
Tyr 88.7 26.9 88.2 12.6 11.4 11.1
Trp 76.5 33.7 83.2 15.7 10.4 9.3
Values are given in kcal/mol.
*Energies are calculated according to DGLIEbind ¼ aDÆVvdWls æ1bDÆVellsæ1g,
and the error in these values is ,1.0 kcal/mol. The coefﬁcients used are
from Model A in Table 4.
yExperimental binding data from Krowarsch et al. (17).
z0 indicates a neutral side chain. DGLIEbind has been corrected with the free
energy required to protonate/deprotonate the ionic side chain according to
DDGpKabind ¼ 1:35jpH  pKaj; where pH is 8.3 (corresponding to the pH used
in the association measurements) and pKa is 4.5 and 4.0 for Glu(5.1 kcal/
mol) and Asp(5.8 kcal/mol), respectively.
§To compensate for ionic residues described with neutral topologies 10.2
kcal/mol has been added to the calculated binding free energies of Lys and
Arg (see Methods).
TABLE 4 Optimized LIE models for binding of P1 variants of OMTKY3 to chymotrypsin and elastase, and P1 variants of BPTI to











Chymotrypsin 0.63 FEP 8.0 0.90 0.74 0.89 0.86 1.10
Elastase 0.56 FEP 9.1 0.61 0.50 0.95 0.93 0.80
Trypsin 0.54 FEP 3.6 1.32 1.03 0.85 0.82 1.59
B
Chymotrypsin 0.65 0.49 7.9 0.87 0.69 0.90 0.85 1.16
Elastase 0.74 0.52 8.2 0.55 0.43 0.96 0.94 0.81
Trypsin 0.57 0.44 3.3 1.30 1.01 0.85 0.79 1.76
C
Chymotrypsin 0.18* FEP 12.5 1.96 1.72 0.47 0.41 2.19
Elastase 0.18* FEP 12.2 1.20 0.92 0.81 0.78 1.38
Trypsin 0.18* FEP 7.1 1.90 1.69 0.69 0.65 2.14
*The a-parameter is not optimized in Model C.
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discussed below. Inspection of the simulated trajectories
shows that the S1 site is clearly enlarged when the aromatic
side chains are accommodated to elastase. The side chain of
Val-216 is also tilted down into the S1 site, making the
entrance to the S1 site more accessible (Fig. 4). Fig. 4 also
shows the predicted binding mode for P1 Ala, and
a comparison with the binding mode for P1 Trp clearly
shows the enlargement of the S1 site resulting from
introducing Trp into the S1 site. There is unfortunately not
any experimental structure available with P1 variants with
which to compare our simulation, but it is apparent that the
features of the native complex are not reproduced by the
simulations of large side chains at the S1 site.
Hot spots of binding tend to be clustered at the center of
the interface (3,39), leading to exclusion of bulk solvent from
the interacting residues. The scaffold of energetically less
important residues surrounding the hot spot regions thus
serves to occlude bulk solvent and provide a suitable dielec-
tric environment. Electrostatic interactions and hydrogen
bonds will increase in strength as the dielectric constant is
reduced at the center of such interfaces. Ionizable side chains
(His, Arg, Lys, Asp, and Glu) are generally predicted from
our calculations to be accommodated in their neutral form to
the S1 sites of the currently investigated proteinases, except
for BPTI P1 Lys and Arg to trypsin. This is not very
surprising as the binding of ionic P1 variants can be thought
of as a transfer of a charge from a medium with a high
dielectric constant to a medium with a low dielectric con-
stant, which is, without taking into account speciﬁc polar
interactions, thermodynamically unfavorable. The P1 resi-
dues of both OMTKY3 and BPTI are fully exposed to sol-
vent in the protein when it is in the unbound state, and only
minor changes in the pKa of these residues are observed
relative to the free amino acid (40). As the free energy
calculations require that the protonation state investigated is
identical in the bound and unbound states, and the P1 Arg,
Lys, Asp, and Glu side chains are expected to be pre-
dominantly ionized in the free inhibitor, the calculations with
a neutral form of these P1 variants need to be corrected by
the free energy required to protonate/deprotonate the side
chain of the P1 residue. The free energy of protonation/
deprotonation is added to the calculated DGLIEbind according to
DDGpHbind ¼ 1:35jpH  pKaj, where pH is 8.3 and the pKa of
the free amino acid side chain is used. The binding free
energy of all the ionizable P1 variants, except for P1 Arg
bound to HLE, are in very good agreement with experimen-
tal data. Our calculations underestimate accommodation of
OMTKY3 P1 Arg to elastase by 3.7 kcal/mol, which is most
likely related to the different deprotonation sites on the P1
Arg side chain, as deprotonation of the Arg side chain results
in several resonance structures. Still, the calculations show
that not only can the effect of point mutations be predicted
with a high level of accuracy, but the methodology outlined
here also presents an easy and fast procedure to determine
the protonation state of residues at protein-protein interfaces.
Active site preorganization energy
Several factors have been proposed to give rise to different
parameterizations of the LIE equation, such as the choice of
FIGURE 1 Scatter diagrams of the calculated versus the experimental binding free energy (kcal/mol) using model A for binding of P1 variants of OMTKY3
to chymotrypsin and elastase and BPTI to trypsin.
FIGURE 2 Surface representation of the crystal structure of trypsin in
complex with the P1 Trp variant of BPTI (Protein Data Bank accession code
3BTW). BPTI is shown in tan with the P1 residue colored red.
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force ﬁeld, computational protocols, properties of the active
site etc. Possible force ﬁeld dependencies have been sys-
tematically investigated and the method was shown to yield
virtually identical coefﬁcients when studying binding of nine
ligands to P450cam with three different force ﬁelds (14).
One of the cornerstones of simpliﬁed free energy methods
such as LIE (6) and LRA (15) is the electrostatic linear re-
sponse approximation, which approximates the free energy
of charging a solute as in Eq. 3. LIE makes the additional
approximation that ÆVellsæoff is negligible. The motivation for
this is that in the off state the solvent molecules relax, i.e.,
they orient themselves randomly relative to the solute, and
thereby their electrostatic interactions with the solute will
average to zero (13). Two major advantages of neglecting
ÆVellsæoff are that only one simulation is needed (of the
physical ligand) for bound and unbound states, and the very
slow convergence of ÆVellsæoff is avoided. The LIE method
also utilizes the linear response approximation along with the
aforementioned simpliﬁcation in the complexed state. It is
not obvious beforehand that this is a valid simpliﬁcation in
the bound state, since binding sites often have a seemingly
preorganized electrostatic environment (in particular, e.g.,
enzymes for their transition states) which might not relax
completely in the off state. For small drug-like solutes it ap-
pears that the assumption that ÆVellsæoff is negligible in the
binding site holds. It is not completely clear if this originates
from binding site relaxation or randomized orientations of
the (unphysical nonpolar) solute relative to its binding site,
i.e., ligand relaxation. For protein ligands such as OMTKY3,
both ligand and receptor relaxation could be severely re-
duced since the P1 residue is anchored in place by the sec-
ondary interactions between the rest of OMTKY3 and
chymotrypsin. In this case, the lack of relaxation would yield
a ÆVellsæoff term that is not zero.
To elucidate the effects of neglecting the preorganization
term we have evaluated ÆVellsæoff for several ligands in water
and bound to their respective proteins. Plotted in Fig. 5 is the
free energy contribution of DÆVellsæoff versus DÆVvdWls æ for
three different systems: chymotrypsin with P1 mutants of
OMTKY3, trypsin with benzamidine analogs, and P450cam
with camphor analogs. As can be seen in Fig. 5, neglecting
ÆVellsæoff without any compensation will lead to signiﬁcant
errors in the calculated DGbinds for the protein-protein sys-
tem. Also evident in Fig. 5 is a size dependence of ÆVellsæoff
FIGURE 3 Representative snapshot of most
and least favored P1 variants bound to chymo-
trypsin (A and B), elastase (C and D), and trypsin
(E and F). Only the binding loop of the inhibitors
and the molecular surface of the proteinases are
shown for clarity.
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for the protein-protein system. The slow convergence of
ÆVellsæoff has most likely imparted large errors in the values of
DGeloff , but, nonetheless, the general trend is evident. It is,
however, remarkable that the calculations show essentially
no preorganization effect for the small ligand data set, which
suggests a complete relaxation for these compounds. The
protein-protein system has a slope of 0.19, whereas the small
ligand data set has a slope close to zero (0.01). The dif-
ferent slopes of the regressions can be directly related to the
different values of a obtained for the protein-protein system
and the small-ligand systems. This can bee seen by reparam-
eterizing the LIE model using parameterization A, with the
combined values of ÆVellsæoff and ÆVellsæon instead of only
ÆVellsæon. As expected, this reparameterization yields an a of
0.43, but with worse statistics than the original parameter-
ization A (Q2 of 0.72 compared to 0.86), which is probably
due to intrinsically bad convergence of ÆVellsæoff . It should be
noted here that the convergence problem for this quantity
mainly resides in the fact that sampling is done with the
unphysical potential (nonpolar ligand), whereas a physical
average (polar ligand) is collected.
It is thus clear that ÆVellsæoff contributes to the binding free
energy of OMTKY3 to chymotrypsin and is most likely
important for binding of BPTI to trypsin and OMTKY3 to
elastase. However, our results suggest that this effect can be
incorporated into the empirical a parameter and that this
approach yields more accurate results than explicitly eval-
uating the preorganization term, which requires extra simu-
lations (41) and is associated with intrinsic uncertainties. It
appears, however, that the preorganization term does not
account for the entire effect observed here on the a pa-
rameter, indicating that there may be other size-dependent
binding energy contributions that differ between smaller li-
gands and protein-protein complexes. One such possible fac-
tor has to do with translational and rotational entropy losses
upon binding. These are clearly also parameterized into Eq. 1
and it may be argued that relative entropy changes between
different ligands are more sensitive to ligand size for smaller
molecules that are not anchored by secondary interactions
(C. Carlsson and J. A˚qvist, unpublished). Such an effect
would also tend to yield a high a value for protein-protein
complexes.
FIGURE 4 Binding of OMTKY3 P1 Trp (A) results in major structural
rearrangements at the S1 site of elastase compared to accommodation of
OMTKY3 P1 Ala (B). Only the binding loop of OMTKY3 and the
molecular surface of HLE are shown for clarity.
FIGURE 5 (A) The contribution of binding-site preorganization to the
binding free energy versus the difference in Lennard-Jones energies between
bound and free states. The P1 variants of OMTKY3 complexed with
chymotrypsin are shown as diamonds. Small ligands (ligands to p450cam
and benzamidine-like ligands) are shown as stars. (B) The size dependence
of the electrostatic preorganization energy contribution to the binding free
energy for P1 variants of OMTKY3 binding to chymotrypsin ()) and small
ligands binding to their receptors (:). On the horizontal axis is the number
of heavy atoms in the P1 amino acid or small ligand.
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CONCLUDING REMARKS
The experimental association constants for binding of P1
variants of OMTKY3 to chymotrypsin and elastase and of
BPTI to trypsin yields free energies of binding ranging from
–5.6 to –18.4 kcal/mol depending on the P1 residue accom-
modated at the S1 site of the enzyme. These complexes thus
display some of the highest binding constants measured for
noncovalent associations, and it is striking that mutations of
a single amino acid can alter the binding energy by as much
as 12–13 kcal/mol. To be able to predict the effect of such
point mutations before laboratory experiments will therefore
have a tremendous impact on the understanding of the spec-
iﬁcities of particular interaction sites, and potentially lead to
more rationalized research. We have here presented a com-
putational model that accurately predicts the effect of point
mutations at protein-protein interfaces. This model is dif-
ferent from the LIE model used to study complexes of
smaller ligands with proteins, with the main difference being
the treatment of the hydrophobic contribution to the binding
free energy. Observations that the nonpolar contribution to
solvation free energies of solutes scales linearly with typical
size measures, and that ÆVvdWls æ also scales linearly with such
size measures, led to the assumption that ÆVvdWls æ will scale
linearly with nonpolar solvation free energies. It has been
shown in many previous studies that this basic idea is sound
and the combined proportionality constant is 0.18 for com-
plexes of smaller ligands with proteins. In this work we have
found that the binding energetics of mutations at protein-
protein interfaces yields a different parameterization of the
method and that the reasons for this can be understood. The
nonpolar coefﬁcient obtained here is virtually identical for
the three systems investigated, with a variation of ,0.09.
This indicates that the a may be transferable to other
proteinase-protein inhibitor systems, but further study is
needed to investigate this in detail.
One of the central assumptions made in this study is that
the contribution from secondary subsites to the interaction
free energy does not change when introducing different amino
acids at the P1 position. This assumption does not seem to
hold when large side chains are inserted into the S1 site of
elastase, and the corresponding free energies indicate that the
methodology does not work well in such cases. However,
these issues cannot be fully resolved until crystal structures
of proteinase-protein inhibitor complexes where very large
side chains are inserted into narrow active sites become
available. This situation also emphasizes the importance of
a thorough structural analysis of the simulated trajectories to
verify that the assumption holds. Nonetheless, the assump-
tion that the secondary interactions do not change upon
complex formation, which is based on crystallographic anal-
ysis of several P1 protein-protein complexes displaying vir-
tually identical secondary interactions, seems to hold for 52
out 56 investigated complexes. When experimental binding
data is available, the contribution from the secondary inter-
actions can be estimated by ﬁtting the g-parameter to repro-
duce the absolute binding free energies. On the contrary, if
there are no binding constants available, only relative effects
can be computed, as the g-parameter always cancels out in
the relative binding free energies. This constant will also
vary depending on which proteins form the complex.
The quantitative agreement with experimental data for our
set of 52 mutants is very encouraging and although our data
set of mutations is rather large it is, nevertheless, clearly of
interest to examine other protein-protein interfaces to deter-
mine the generality of the model derived herein. It is also
encouraging that 44 of the complexes investigated are ho-
mology models, and only one crystal structure was used to
generate the full series of complexes for chymotrypsin and
one for elastase. This indicates that x-ray structures are not
needed to obtain accurate energetic predictions, though more
investigations on complexes for which there are no crystal
structures available need to be carried out to fully address
this. It is highly desirable to have a reliable microscopic
computational approach for predicting the energetics of both
single and multiple mutations at interfaces and, in this re-
spect, it seems possible to extend our LIE treatment also to
multiple mutations. To investigate this in further detail, a
study covering binding of the canonical protein inhibitor
eglin c to several subtilases with multiple mutations at P1,
P4, and P6 has been initiated. Preliminary results show that
the LIE model derived herein is indeed capable of dealing
with multiple mutations. For two particular proteins, furin
and kex2, crystal structures of the complexes with eglin c are
not available, but still the energetic effects of point muta-
tions, calculated by the method outlined here, provide rel-
ative binding free enegies that are in very good agreement
with experimental data (B. O. Brandsdal, S. M. Mekonnen,
and A. O. Smala˚s, unpublished).
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